DMRA Overview

Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.

Wall Street analysts forecast DMRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Damora Therapeutics Inc revenue for the last quarter amounts to -27.39M USD, increased 911.67

Damora Therapeutics Inc. EPS for the last quarter amounts to 566000.00 USD, decreased -111.47

Damora Therapeutics Inc (DMRA) has 7 emplpoyees as of March 25 2026.

Today DMRA has the market capitalization of 1.44B USD.